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The eﬀects of Arnica montana 6cH on the individual modulation of acute inﬂammation kinetics in rats were evaluated. Adult
male Wistar rats were inoculated with 1% carrageenan into the footpad and treated with Arnica montana 6cH, dexamethasone
(4.0mg/kg; positive control) or 5% hydroalcoholic solution (negative control), per os, each 15 minutes, between 30 and 180
minutes after the irritant inoculation.Histopathological and immunohistochemistry procedures were done in order to get a panel
ofinﬂammatorypositivecells forCD3(Tlymphocytes),CD45RA(Blymphocytes),CD18(beta 2integrin),CD163(ED2protein),
CD54(ICAM-1),andMAC387(monocytesandmacrophages).The statisticaltreatment ofdataincluded aposteriori classiﬁcation
ofanimalsfrom each group (N = 20) in two subgroups presenting spontaneous precocious orlate oedema. Animals thatpresented
precocious oedema were less responsible to Arnica montana 6cH in relation to hemodynamic changes. Instead, rats that exhibited
late oedema presented less intense oedema (P = .01), lower percentage of mast cell degranulation (P = .0001), and increase in
lymphatic vessels diameter (P = .05). The data suggest an individually qualitative adjustment of inﬂammatory vascular events by
Arnica montana 6cH.
1.Introduction
One of the most discussed controversies about the eﬃcacy
of homeopathic medicines is the necessity to identify a
perfect symptomatic analogy between patient and drug
pathogenesy, that is, the necessity of individual prescription
according to the similia principle. This particular feature
is one of the most diﬃcult challenges of the scientiﬁc
research in this ﬁeld because of the technical diﬃculty of
its experimental demonstration. Indeed, few experimental
studies about are found in the literature [1–6]. Thus, the
experimental demonstration of this particularity and the
comprehensionofitsmechanisms canbeusefultoolstosolve
the chronic controversies about homeopathy eﬃcacy, often
seen in clinical trials [7, 8]. Recently,an elegant in vitro study
demonstrated the importance of the regulatory and adaptive
cell mechanisms in the magnitude of homeopathic remedies
inducing cytotoxic eﬀects on cancer cells [9].
From 1997 up to 2008, we have developed a step-by-
stepresearch trial aboutthebiologicaleﬀectsofhomeopathic
Arnica montana, specially the Arnica montana 6cH, using
animalmodels[10–13].Inshort,theresultsobtainedinthese
studies show that Arnica montana 6cH is able to modulate
the acute inﬂammatory process in rats, since it can increase
lymphaticoedemaabsorption and localbloodﬂow, aswell as
to promote the array of polymorphonuclear cell migration.
All these experiments are chronologically described in [13].
The Arnica montana is a plant belonging to the Com-
positae family that grows on the hills of East and Central
Europe. Several active compounds are identiﬁed in its leaves,
ﬂowers, and roots, such as alcohols, tannin, ﬂavonoids, and
sesquirterpenic lactones, especially helenalin [14]. The main
action of helenalin is the inhibition of the transcription fac-
tor NFκβ, similarly to corticoid steroids [15]. The incidental
ingestion of the plant can cause vasodilatation, blood stasis,
hemorrhage, oedema, and pain. These eﬀects are the main
topics described in the Arnica montana materia medica [14].
Because of that, trauma pain and oedema absorption are
the main indications for the clinical and experimental use
of homeopathic preparations of Arnica montana [16–20].2 Evidence-Based Complementary and Alternative Medicine
Table 1: Groups and treatments.
Group Treatment Administration
Arnica montana 6cH each 15 minutes, between 30 and 180 minutes
from inoculation, orally, using automatic pipette
10μL/100g body weight per administration
(total of 8 administrations)
5% hydroalcoholic solution idem 10μL/100g body weight per administration
(total of 8 administrations)
Dexamethasone (Azium) idem
10μL/100g body weight per administration
(the total dose of 4mg/kg was fractioned
along 8 administrations)
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Figure 1: Oedema (mm) in diﬀerent groups and subgroups. (a) Evolution of oedema in function of time in the early oedema subgroup;
(b) evolution of oedema in function of time in the late oedema subgroup; (c) intensity of oedema at the end of the experiment in the early
oedema subgroup; (d) intensity of oedema at the end of the experiment in the late oedema subgroup. ∗P = .01; ANOVA, Tuckey-Krammer, in
relation to control. The values represent mean ± standard deviation.
Recently, other uses of high diluted Arnica montana have
been proposed, like the agronomic use of Arnica in the
potencies 3, 6, and 12cH to improve plants growth [21].
The aim of the present study was to check two hypothe-
ses: (a) the putative modulation of vascular and cell events
in acute inﬂammation by Arnica, focusing on the rate of
neutrophils, monocytes, T and B lymphocytes present in the
inﬂammatory site, and the intensity of adhesion molecules
expression in inﬂamed connective tissue, using immuno-
histochemical and histomorphometrical techniques; (b) the
putativeinterference onthe outputsofthe natural individual
variations of inﬂammation kinetics.Evidence-Based Complementary and Alternative Medicine 3
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Figure 2: Histogram representing the percentage of degranulated mast cells and lymphatic area (pixels) per ﬁeld. (a) Subgroup that
developed earlier oedema; (b) subgroup that developed later oedema. ∗X2, P = .0001 in relation to control. ∗∗Kruskal-Wallis, P ≤ .05
in relation to dexamethasone group.
2.MaterialandMethods
2.1. Animals. Male adult Wistar rats, weighting between 250
and 300g, were used. Rats were maintained in conventional
laboratory polypropylene cages (5 to 7 animals per cage),
with controlled temperature (25±3◦C) and light cycle
(lightsonfrom06:00AMto 06:00PM). Water and food were
oﬀered ad libitum. Prior to the beginning of the experiment,
animals were randomly weighed, separated, and identiﬁed in
three groups of 20rats each.
2.2. Induction of Acute Inﬂammation. The acute inﬂamma-
tory process was induced by the subcutaneous inoculation of
1% kappa carrageenan (SIGMA) diluted in sterile saline into
the footpad, whose thickness was previously measured with
am i c r o m e t e r( M Y T U T O Y O ) .
After30and180minutes,newmeasurementsweremade,
in order to evaluate the pre- and posttreatment oedema
evolutioninfunctionoftime.Thus,theﬁrst30minutes mea-
sured the spontaneous oedema formation and the remaining
150minutesmeasured thedrugeﬀects,sincetreatmentswere
done after the 30-minute measurement. At 180 minutes,
animals were euthanized by cervical traction under deep
anesthesia, and foot pads were harvested and ﬁxed in
buﬀered 10% formaldehyde during 24 hours—maximum—
before being processed by conventional histological tech-
niques, including paraﬃn embedding, hematoxylin-eosin,
and toluidine blue staining. The same paraﬃn blocks were
used to perform the immunohistochemical procedures. For
each footpad, one single slide was done.
2.3. Groups and Treatments. Each group of rats was treated
with a speciﬁc substance, according to Table 1. Rats treated
with Arnica montana 6cH (experimental) and unsuccussed
5%hydroalcoholicsolution(negativecontrol)obtainedfrom
the same supplier were identiﬁed by codes, in a manner that
all treatments and measurements were made in blind. These
codes were created by a laboratory technician who did not
participate of the study and kept in a sealed sheet up to the
statistical analysis, when they were revealed.4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Histogram representing the number of MAC387 positive cells per ﬁeld, the CD163/MAC387 ratio and the number of
polymorphonuclearcells per ﬁeld. (a)Subgroup thatdeveloped earlier oedema;(b) subgroupthatdeveloped lateroedema. ANOVA,without
signiﬁcance.
The dexamethasone-treated rats (positive control) were
made openly, because of the physical characteristics of
the used formulation; it was quite diﬀerent from the
homeopathic ones and, thus, easily recognizable. The
treatment and the microscopic analysis of samples were
performed by two independent persons, always in blind.
The total dose of dexamethasone used to produce anti-
inﬂammatory eﬀects was 4mg/kg, according to the stan-
dards deﬁned previously [22]. This fractioned protocol
was designed to reproduce a usual homeopathic clinical
condition of acute inﬂammation treatment and was also
used in the previous studies performed by our group [13].
Dexamethasone was chosen as a positive control group
because its mechanism of action mimics the mechanism
of helenalin, the main active principle of Arnica montana
[13, 15].
The commercial Arnica montana 6cH was prepared in
5% hydroalcoholic solution by a pharmacy certiﬁed by the
regulatory Brazilian National Agency for Sanitary Vigilance
(ANVISA), Farm´ acia Sensitiva,S ˜ ao Paulo. The techniques
used in the preparation were according to the Brazilian
Homeopathic Pharmacopea, 2nd Edition, 1997.
2.4. Data Analysis. After the ﬁrst plotting of the oedema
intensity obtained during the pretreatment period (from
zero to 30minutes), data were classiﬁed in crescent orderingEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Histogram representing the number of CD3 and CD45R positive cells per ﬁeld. (a) Subgroup that developed earlier oedema;
(b) subgroup that developed later oedema. ANOVA, without signiﬁcance.
using an Excel 2003 software, in a way that it would
be possible to divide, for each group, the 10rats (50%)
that presented spontaneously lower oedema intensity and
the 10rats (50%) that presented higher oedema intensity.
Thus, two subgroups of 10 animals were formed for each
experimental group,characterizing twodiﬀerentrat subpop-
ulations according toinﬂammatory kinetic pattern(Table 2).
The whole experimental design is explained in a ﬂowchart
(Figure 7).
Since the classic curve of carrageenan-induced oedema
is over up to 6 hours after inoculation, the choice of
both times (30 and 180 minutes) was based on its known
plateau [23, 24]. Moreover, previous studies about the eﬀects
of Arnica 6cH upon carrageenan-induced oedema show
no more eﬀe c t sa f t e rt h i sp e r i o d[ 10, 11]. The kinetics
of inﬂammatory process evaluation after the injection of
carrageenan are a classical experimental model developed
during the 70s [23, 24]. Thus, it is a trustful criterion to be
used in this case.
After plotting data (Figures 1(a) and 1(b)), both kinetic
patterns became easy to identify: (a) animals that presented
less intense oedema during the ﬁrst pretreatment 30minutes
had the peak between 30 and 180 minutes (named late
oedema) and (b) those that presented more intense oedema
in the ﬁrst 30 minutes decreased after this period (named
early oedema).
All results were compared among the six subgroups. This
a posteriori selection was made in order to check the role of
individual idiosyncrasy in the Arnica eﬀect according to the
similia principle, since the speed of oedema remission is one
of the most known Arnica montana symptoms described in
materia medica [10, 11, 13, 14].
2.5. Immunohistochemical Analysis. All slides were washed
with 1:1 alcohol-ether solution during ﬁve minutes and
then dried with a soft sheet of paper and treated with 1:10
poly-L-lysin (SIGMA). Then, 5 microns paraﬃn-embedded
tissue slices were transferred to their surface using a 40◦C
histological bath. Next, slices were deparaﬃned through two
baths in absolute xylol for 2 minutes and two baths in
absolute alcohol for 3 minutes. Slides were, then, washed in
current tap water.6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Histogram representing the number of CD18 (beta 2 integrin) positive cells per ﬁeld and the median (interval) of scores of CD54
(ICAM) labeling. (a) Subgroup that developed earlier oedema; (b) subgroup that developed later oedema. ANOVA, without signiﬁcance;
∗Kruskal-Wallis/Dunn, P = .03 in relation to control.
Table 2: Schedule of groups and subgroups post-classiﬁed after the
ﬁrst oedema measurement (30 minutes).
Groups Subgroups Oedema peak
Arnica montana
6cH (n = 20)
Early oedema
(n = 10)
Up to 30minutes
(pretreatment)
Late oedema
(n = 10)
Between 30 and 180 minutes
(post-treatment)
Dexamethasone
(4mg/kg) (n = 20)
Early oedema
(n = 10)
Up to 30minutes
(pretreatment)
Late oedema
(n = 10)
Between 30 and 180 minutes
(post-treatment)
5% Hydroalcoholic
solution (n = 20)
Early oedema
(n = 10)
Up to 30minutes
(pretreatment)
Late oedema
(n = 10)
Between 30 and 180minutes
(post-treatment)
For the immunohistochemistry procedures, a ﬁrst step
for antigen retrieving was made using heat treatment of
samples.Slideswereputinsideacitratebuﬀerbath(SIGMA),
pH=6.0, containing 0.5% tween 20 (DAKO), and heated in
an electric pot at 80◦C (PANASONIC) during 20 minutes.
After that, slides were washed in PBS, pH=7.2 (SIGMA), for
6 minutes and dried with a soft absorbent paper, and the
tissue sample was delimited using an appropriate pen (Pap-
pen, AbCam).
The endogenous peroxidase activity was blocked by
incubation of tissues in a 3% H2O2 solution diluted in
methanol (ISOFAR), for 15minutes at room temperature.
Then, they were washed in PBS (SIGMA) for 6 minutes and
treated with 2.5% horse normal serum (VECTOR) during
20 minutes at 25◦C, for blocking unspeciﬁc protein-binding
sites. Immediately after this step, the tissues were treated
with the primary antibody (see dilutions and speciﬁcations
in Table 3) and left standing overnight at 4◦Ci nah u m i d
chamber. All dilutions of primary antibodies were made in
1% bovine serum albumin (BSA).
In the next day, cuts were washed in PBS (sigma)
for 6 minutes and treated with the polymer-peroxidase-
conjugated secondary antibody (IMPRESS UNIVERSAL,
VECTOR), at 25◦C during 30 minutes. After a new washing
in PBS (6 minutes), they were exposed to DAB (DAKO)
for 3seconds, washed once again in tap water, stained with
Harris hematoxylin (01minute), and mounted.Evidence-Based Complementary and Alternative Medicine 7
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Figure6:Scatteringplottingshowingdiﬀerenttrendsofoedematimeevolutionbetween bothsubgroups.Thewhitepointsrepresentcontrol,
the black points represent Arnica montana 6cH, and the grey points represent dexamethasone. In each graphic, the X-axisshowsthe oedema
at30minutes beforecarrageenaninjectionandtheY-axisshowstheoedemaattheendofexperiment. LATE =lateoedemasubgroup;EARLY
= early oedema subgroup. Note that animals that presented late peak of oedema and were treated with Arnica montana 6cH are displaced to
t h eb a s e l i n ei nr e l a t i o nt ot h eo t h e rg r o u p s .
2.6. Histomorphometry. For the evaluation of mast cell
degranulationpercentage,twohundredcellsperslidestained
by Toluidine blue method were counted, using contiguous
ﬁelds, diﬀerentiating the degranulated from the nondegran-
ulated ones. To evaluate the lymphatic vessels diameter, ﬁve
ﬁelds chosen by chance were evaluated using a 200x objec-
tive.Photomicrographsofeachﬁeldweremade(CANNON),
and the percentage of lymphatic vessels area per ﬁeld was
determined by a digital image analysis system (Image Tool
3.0). The diameter of lymphatic vessels can be considered as
a good parameter to evaluate lymphatic oedema absorption,
according to previous observations [13]. As the protocol was
about acute events, the hypothesis of lymphangiogenesis was
not considered.
For the anti-CD45RA, CD3, CD18, CD163, and MAC
387 markers, ten microscopic ﬁelds chosen by chance were
observed per slide, using immersion objective (magnitude
1000x). They included almost all the subcutaneous vascular
c o n n e c t i v et i s s u e so ft h ep a d ,a n dt h en u m b e ro fp o s i t i v e
cells per ﬁeld was recorded. In the case of Anti-MAC
387, only mononuclear positive cells were considered. The
hematoxylin-eosin-stained slides were used to count the
number of PMN cells per ﬁeld. In this case, the recognition
of cells was made only by morphological criteria. The
expression of CD163 is proportional to the macrophage
maturation, because of that, these results were expressed as
the ratio between CD163/MAC 387 mononuclear positive
cells per ﬁeld.8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: Flowchart of the experimental steps, determining two subgroups of rats according to the oedema kinetic.
For the Anti-CD54, the intensity of positivity on the
endothelial cells surface was evaluated by a score system,
varying from 1 to 4. Five ﬁelds chosen by chance were evalu-
ated by slide, using immersion objective (magnitude 1000x),
and the scores were done by two independent observers,
in a blind manner, to avoid subjective interpretation in the
analysis. The ﬁnal score for each slide was equal to the
sum of the partial scores. The criteria of score grading are
represented in Table 4.
2.7.Statistical Analysis. The Bartletttestwasﬁrstly employed
to determine the Gaussian distribution of the majority of
data points. Then, ANOVA/Tuckey-Krammer or Kruskall-
Wallis/Dunn was performed, according to the Bartlett
results. The evaluation of mast cell degranulation, instead,
was evaluated by X2 test. The values of P ≤ .05 were
considered signiﬁcant. All statistical analysis was performed
using the INSTAT 3 software.
Inrelationtooedema,anadditionalintragroupstatistical
analysis was also performed, and the comparison of oedema
intensity among subgroups at 30 minutes (spontaneous
oedema) revealed signiﬁcant diﬀerences (Tuckey-Krammer,
P ≤ .01), validating the proposed experimental design.
2.8. Bioethical Criteria. The protocol was approved by the
Bioethics Committee of Universidade Paulista (protocol
011/07), according to the S˜ ao Paulo State law no. 11.977/05
(AnimalprotectioncodeofS˜ aoPauloState,Brazil).Thispro-
cedure is in accordance with the European Convention for
the Protection of Vertebrate Animals used for Experimental
and Other Scientiﬁc Purposes and its appendix.
3.Results
The histopathological aspect of inﬂamed footpads revealed
the classic framework of a typical early acute inﬂammation:
oedema and cell inﬁltrate corresponding to 2/3 of PMN
cells and 1/3 mononuclear cells. However, considering the
intragroup statistical treatment, the existence of diﬀerent
patterns of inﬂammatory process development in function
of time could be identiﬁed (Tables 5 and 6). Thus, there was
the necessity to systematize and classify these patterns before
analyzing the eﬀects of Arnica montana 6cH.
According to that, a signiﬁcant antioedematous eﬀect of
Arnica montana 6cH could be seen (ANOVA, P = .01) only
in the subgroup of rats that presented the peak of oedema
between 30 and 180 minutes after the injection of car-
rageenan into the footpad (called late subgroup)( F i g u r e1).
Also, the histomorphometric analysis of slides stained by
Toluidine blue revealed that the late subgroup also presented
less intense mast cell degranulation (X2, P = .0001) and
greater diameter average of lymphatic vessels (Kruskal-
Wallis, P ≤ .05). Instead, in the early subgroup (oedema peak
before 30minutes), only a discrete but signiﬁcant increase in
mastcelldegranulationwasobserved(X2,P = .0001),aswell
as increase in scores of CD54 expression by endothelial cells
(Kruskal-Wallis, P = .05) (Tables 5 and 6,F i g u r e s2 and 5).
No diﬀerence among groups and subgroups was
observed regarding cell migration, considering PMN cells
and all markers used in the immunohistochemical analysis,
including the CD 163+/MAC 387+ cells ratio (Tables 5 and
6,F i g u r e s3, 4,a n d5).
Taking all data together, it is possible to illustrate the
main conclusion by a scattering graph of oedema intensity,
in which the diﬀerent trends among groups and subgroups
can be seen, after the treatment with Arnica montana 6cH
(Figure 6). Note that animals treated with Arnica and
exhibiting late oedema (late subgroup)a r ed i s p l a c e dt ot h e
baseline in relation to the other groups.
4.Discussion
Among the homeopathic medicines that have special interest
in inﬂammation control [3, 25, 26], Arnica montana is one
of most studied [16–20].Nevertheless, intherecent scientiﬁc
literature about homeopathy, there are many studies search-
ing to demonstrate the eﬃcacy of its eﬀect, but few works
are devoted to the comprehension of physiopathological
changes in tissues after the exposition of animals to these
medicines [6, 27, 28]. Is from this point of view thatEvidence-Based Complementary and Alternative Medicine 9
Table 3: Markers used in the immunohistochemistry.
Marker Cell Supplier Molecular target Clone Origin
species/target Dilution
Anti-CD54 Activated
endothelial cell Serotec Adhesion molecule
(ICAM 1) 1A29 Mouse-rat 1:10 (5μg/mL)
Anti-CD18 Leukocytes Serotec Adhesion molecule
(Integrin β2) WT.3 Mouse-rat 1:10 (5μg/mL)
Anti-CD163 Monocytes and
macrophages Serotec Surface glycoprotein
(ED2) ED2 Mouse-rat 1:10 (5μg/mL)
Anti-MAC 387 Moncytes,
macrophages AbCAM Intracytoplasmic
protein (calprotectin) polyclonal Rabbit-rat 1:20 (50μg/mL)
Anti-CD45RA B Lymphocytes Serotec Surface protein (LCA) OX-33(B cells only) Mouse-rat 1:10 (5μg/mL)
Anti-CD3 T Lymphocytes AbCAM TCR-associated protein polyclonal Rabbit-rat 1:5 (40μg/mL)
Table 4: Criteria of score attribution for diﬀerent patterns of endothelial cell marking.
Score Description Photomicrography (objective 10x)
1 Weak and discontinuous membrane
marking, magnitude 1000x.
2 Regular but discontinuous membrane
marking, magnitude 1000x.
3 Strong but discontinuous membrane
marking, magnitude 1000x.
4 Strong and continuous membrane
marking, magnitude 1000x.10 Evidence-Based Complementary and Alternative Medicine
Table 5: General view of results obtained in rats that developed spontaneous peak of oedema between 0 and 30minutes (early oedema
subgroup) after the injection of 1% carrageenan into the footpad. ∗Kruskal-Wallis,P ≤ .05; #X2, P = .0001 in relation to control. ##ANOVA,
Tuckey-Krammer, P ≤ .05 in relation to the late oedema subgroup (Table 6).
Early oedema subgroup Control (vehicle) Arnica montana 6cH Dexamethasone (4mg/kg)
Paw oedema (180min) 0.63 ± 0.45
a 0.78 ±0.54
## 0.89 ±0.48
##
Degranulated mast cells 14% 20%# 16%
Lymphatic vessels diameter 101.12± 45.25b 108.08 ±84.33 105.95 ±63.06
CD 54 2 (2–6)c 5 (3–8)∗ 4 (3–6)
PMN 158.11 ±29.88
d 172.30 ±21.60 175.90 ±32.52
CD45RA 23.5 ± 35.34 26.33 ±16.37 26.25 ±13.79
CD18 62.11 ± 24.63 52.11 ±17.87 72.88 ±21.58
CD163 37.28 ±6.42 33.22 ±9.56 32.66 ±8.12
MAC 387 46.87 ±7.82 48.8 ±10.11 50.9 ±8.84
CD3 11.11 ±4.04 13.8 ±9.39 12.2 ±4.13
CD163/MAC387 ratio 0.51 0.56 0.60
amean ± standard deviation; millimeters.
bmean ± standard deviation; pixels per ﬁeld.
cmedian and interval; scores attributed by two independent observers.
dmean ± standard deviation; cells per ﬁeld.
Table 6: General view of results obtained in rats that developed spontaneous peak of oedema between 30 and 180minutes (late oedema
subgroup) after the injection of 1% carrageenan into the footpad. ∗Kruskal-Wallis, P ≤ .05; ∗∗ANOVA, P = .01; #X2, P = .0001 in relation
to control.
Late oedema subgroup Control (vehicle) Arnica montana 6cH Dexamethasone (4mg/kg)
Paw oedema (180min) 0.84 ± 0.33a 0.07 ± 0.48
∗∗ 0.51 ±0.55
Degranulated mast cells 24% 17%# 16%#
Lymphatic vessels diameter 108.73 ± 65.34
b 147.32 ± 113.71
∗ 80.13 ±44.64
CD 54 4 (2–7)c 4.5 (2–6) 2 (2–5)
PMN 176.33 ±29.95d 185.60 ±17.16 179.37 ±22.67
CD45RA 22.85 ±17.12 22.77 ±16.20 25.88 ±20.27
CD18 62 ±13.68 56.8 ±23.58 63.11 ±18.82
CD163 31.5 ±14.84 35.66 ±10.34 30.11 ±12.45
MAC 387 47.77 ±8.24 45.2 ±11.53 51.88 ±13.52
CD3 12.66 ±7.98 15.2 ±7.50 14.88 ±5.37
CD163/MAC387ratio 0.60 0.50 0.66
amean ± standard deviation; millimeters.
bmean ± standard deviation; pixels per ﬁeld.
cmedian and interval; scores attributed by two independent observers.
dmean ± standard deviation; cells per ﬁeld.
the present work was built; through a detailed study of the
inﬂamed connective tissue, considering the subsets of cells
that migrate to it, the vessels behavior, and time-dependent
dynamic of this process under the action of Arnica montana
6cH. Interestingly, some eﬀects observed are in accordance
with previous observed results, such as the overture of
lymphatic vessels and the consequent reduction of oedema
[13].
Theﬁrstresultsobtainedherepointtowardaninteresting
fact: the individual analysis of each subgroup shows the
importance of temporality in the eﬀect of Arnica montana
6cH; animals that presented spontaneous late peak of
oedema (after 30minutes from irritant injection) were more
sensible to Arnica than the animals that presented an early
peakofoedema (before30minutes). Inthiscase, theoedema
was even less intense than the control and dexamethasone
treated groups, and this fact was concomitant with the
signiﬁcant reduction of mast cell degranulation and increase
of lymphatic vessels diameter. Both phenomena could con-
tribute to the reduction of macroscopic oedema and diﬀer
from dexamethasone pattern, in which lymphatic vessels
area reduces passively together with the oedema reduction,
as shown in Figure 2.T h i se ﬀect corroborates the results
observed previously in [13].
Carrageenan is a polysaccharide obtained from the
seaweed Chondrus crispus that has the ability to induce local
inﬂammation, without systemic eﬀects [3]. It is classically
known that prostaglandins are generated during the oedema
formation after subcutaneous carrageenan injection by
migrated neutrophils [29]. The observation of antioedemaEvidence-Based Complementary and Alternative Medicine 11
eﬀect of Arnica montana 6cH exclusively in animals that
presented the late pattern of acute inﬂammation points
toward the participation of diﬀerent chemical mediators
in controlling pathways, as demonstrated before in [10,
11]. In this sense, histamine and prostaglandin, mediators
whose peak ofactionoccurstoward 15–30minutes, probably
modulatethisprocessinthelateoedemasubgroup,insteadof
mediators with a very precocious action, such as bradykinin,
w h o s ep e a ki sa b o u t1 0m i n u t e sa f t e rr e l e a s i n g[ 24, 30].
Experimental models designed specially to demonstrate
the importance of individual variation in the eﬀect of home-
opathic medicine were already described before [5, 31, 32],
but never in an inﬂammation protocol. Individuality means
speciﬁcity in homeopathic medicine; in Rocha 2008 [5],
only the naturally hyperactive rats were responsible to Rhus
toxicodendron 200cH treatment, regarding their behavior
in an open-ﬁeld device. On the other hand, Soares 2007
[32] observed that only hypoactive rats were responsible
to Bryonia alba 200cH. These complementary studies show
results compatible to the respective materia medica.T h e
systematic comparison of both studies and others is seen in
[28].
Regarding to PMN and mononuclear leukocyte sub-
t y p e sc e l lm i g r a t i o n ,n od i ﬀerence among groups and sub-
groups was seen, nor the CD163+/MAC387+ ratio revealed
any change in the dynamic of macrophage maturation in
the inﬂammatory site. The CD 163 is a transmembrane
glycoprotein type I, of 175kD, also known as ED2 protein.
Its presence has been described in the mature macrophage
surface, but also in a less intense manner in immature
monocytes and other mononuclear cells in humans. The
expression of ED 2 is associated to the iron metabolism and
increases during the later phases of inﬂammation, because
positive cells have a modulator role, releasing autocrine IL10
[33–35]. The presence of T and B lymphocytes into the
inﬂammatory site could be related to a certain modulator
action [23, 24], which has been suggested in previous studies
about Arnica montana 6cH [13], but not conﬁrmed herein.
The expression of adhesion molecules CD 54 (ICAM-1)
was greater in animals treated with Arnica montana 6cH that
presented early pattern of inﬂammation and was associated
to a greater percentage of degranulated mast cells in the
inﬂamed tissue, but not to a greater leukocyte migration.
Although no mechanistic explanation could be done in this
step of the study, it seems that the global results are split in
two main patterns: those of regulating vascular dynamics,
evident in the late oedema subgroup,a n dt h o s eo fr e g u l a t i n g
cell events, evident in the early oedema subgroup, suggesting
an individual-dependent qualitative adjustment of vascular
and cellular inﬂammation events by Arnica montana 6cH,
as seen in Figure 6.T h e s ed i ﬀerent patterns of variability,
oscillating according to the previous state of the tested
biological system, have been experimentally described in
other experimental contexts with diﬀerent homeopathic
preparations [26, 36–38].
In conclusion, the two proposed hypotheses could be
highlighted: (a) there is no selective modulation of leukocyte
subsets migration by Arnica montana 6cH treatment, but
only vascular regulations, regarding lymphatic absorption,
CD54expression, and histamine degranulation and (b)there
is a clear interference of the individual kinetic variation in
vascular events after treatment with Arnica montana 6cH.
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